Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Imv Inc
(NQ:
IMV
)
N/A
UNCHANGED
Last Price
Updated: 3:58 PM EDT, Apr 28, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Imv Inc
< Previous
1
2
3
Next >
IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
April 08, 2022
From
IMV Inc.
Via
Business Wire
IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting
April 06, 2022
From
IMV Inc.
Via
Business Wire
IMV Inc. to Present at Two Upcoming Investor Conferences
April 04, 2022
From
IMV Inc.
Via
Business Wire
IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results
March 17, 2022
From
IMV Inc.
Via
Business Wire
IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform
February 17, 2022
From
IMV Inc.
Via
Business Wire
IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL
January 12, 2022
From
IMV Inc.
Via
Business Wire
IMV Inc. to Present at Two Upcoming Investor Events
January 05, 2022
From
IMV Inc.
Via
Business Wire
IMV Appoints Andrew Hall as Chief Executive Officer
December 22, 2021
From
IMV Inc.
Via
Business Wire
IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts
December 21, 2021
From
IMV Inc.
Via
Business Wire
IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility
December 20, 2021
From
IMV Inc.
Via
Business Wire
Role of B Cells Induced by IMV’s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress
December 02, 2021
From
IMV Inc.
Via
Business Wire
IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer
November 30, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference
November 23, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. Announces Chief Financial Officer to Retire
November 22, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update
November 10, 2021
From
IMV Inc.
Via
Business Wire
Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
November 09, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021
November 04, 2021
From
IMV Inc.
Via
Business Wire
Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
October 07, 2021
From
IMV Inc.
Via
Business Wire
Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting
October 01, 2021
From
IMV Inc.
Via
Business Wire
IMV’s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
September 30, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. to Present at Three Investor Conferences in September
September 01, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results
August 11, 2021
From
IMV Inc.
Via
Business Wire
IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer
August 10, 2021
From
IMV Inc.
Via
Business Wire
IMV Announces CEO Transition
August 04, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021
August 02, 2021
From
IMV Inc.
Via
Business Wire
IMV to Participate in the BTIG Virtual Biotechnology Conference
July 29, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. Closes Previously Announced Public Offering
July 20, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. Announces Pricing of Public Offering
July 15, 2021
From
IMV Inc.
Via
Business Wire
IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Units
July 14, 2021
From
IMV Inc.
Via
Business Wire
IMV Announces Annual and Special Meeting of Shareholders Voting Results
June 18, 2021
From
IMV Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.